• Belantamab ELISA Kit
1 1

AntibodySystem

KDF92401

Belantamab ELISA Kit

Belantamab ELISA Kit

Title

Catalog No.: KDF92401

Catalog No. KDF92401
Product name Belantamab ELISA Kit
Size 96 T
Description PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD269 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Belantamab in the sample competitively binds to the pre-coated protein with biotin-labeled Belantamab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Belantamab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications Used for the quantitative determination of Belantamab concentration in serum and plasma.
Stability and Storage When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Detection method Colorimetric
Precision CV<20%
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 102.61 ng/mL
Range 156.25 - 10,000 ng/mL
Recovery 80-120%
Background Belantamab mafodotin also known as GSK2857916 is a humanized, IgG1 antibody-drug conjugate (ADC) that binds specifically to BCMA. The parent anti-BCMA antibody (GSK2857914) is produced in an afucosylated form and is conjugated to the microtubule polymerization inhibitor MMAF, via a protease-resistant maleimidocaproyl (mc) linker, to produce the GSK2857916 ADC molecule. Upon binding to the cell surface, GSK2857916 is rapidly internalized and active cytotoxic drug (cys-mcMMAF) is released inside the cell causing cell-cycle arrest and apoptosis. Furthermore, the afucosylation of GSK2857916 leads to enhanced binding to FcγRIIIa receptors on the surface of immune effector cells, recruitment of immune cells, and antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively). This dual mechanism of action enables improved efficacy by targeting both dividing (via ADC) and non-dividing (via ADCC/ADCP) tumor cells. Recently, belantamab mafodotin was approved under the name BLENREP in the United States and European Union for the treatment of patients with relapsed or refractory multiple myeloma.
Alternative Names 2857916, GSK2857916, J6M0, J6M0-mcMMAF, CAS: 2061894-48-0
Shipping 2-8 ℃
Note For Research Use Only.
전체 세부 정보 보기